


7

Closing remarks

# TRACK RECORD OF STRONG EXECUTION WITH UPCOMING VALUE INFLECTION POINTS



# CLINICAL AND PRECLINICAL PIPELINE

Product candidate	Preclinical	Phase 1	Phase 2	Collaborator	Next expected event
ONCOS-102	Melanoma Combination w/anti PD1				<b>1H 2022</b> First patient
	Colorectal cancer Combination w/Imfinzi			AstraZeneca CANCER RESEARCH INSTITUTE	<i>Updates by collaborator expected 1H22</i>
	Mesothelioma Combination w/pemetrexed/cisplatin			MERCK	<b>1H 2021</b> Survival update
ONCOS-200 series	Next Gen viruses			leidos Papyrus	<i>Updates at conferences</i>
Novel mutRAS concepts				VALO THERAPEUTICS OBLIQUE THERAPEUTICS	

# EARLY-STAGE DEVELOPMENT SUCCESSFULLY COMPLETED – ENTERING LATE-STAGE DEVELOPMENT

## Early-stage development

- ✓ Clinical efficacy
- ✓ Immune activation
- ✓ Well tolerated

## Late-stage development

PD1 refractory melanoma



## Expansion opportunities

- Mesothelioma
- Colorectal cancer
- Other indications
- Other IO combinations
- Platform development